Douglas Blayney
Director/Board Member at ARTELO BIOSCIENCES, INC.
Net worth: 1 118 $ as of 29/04/2024
Profile
Douglas W.
Blayney is the founder of Asco Quality Symposium.
He currently holds the position of Independent Director at Artelo Biosciences, Inc. since 2017 and is a Professor at Stanford University since 2010.
Previously, he served as the Medical Director & Professor at the University of Michigan Comprehensive Cancer Center from 1999 to 2003, the Medical Director at Stanford Cancer Institute from 2010 to 2015, and the President of the American Society of Clinical Oncology, Inc. from 2009 to 2010.
He completed his undergraduate education at Stanford University and the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARTELO BIOSCIENCES INC
0.03% | 21/03/2024 | 834 ( 0.03% ) | 1 118 $ | 29/04/2024 |
Douglas Blayney active positions
| Companies | Position | Start |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Director/Board Member | 30/07/2017 |
| Stanford University | Corporate Officer/Principal | 30/06/2010 |
Former positions of Douglas Blayney
| Companies | Position | End |
|---|---|---|
| Stanford Cancer Institute | Corporate Officer/Principal | 30/06/2015 |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | President | 30/06/2010 |
| University of Michigan Comprehensive Cancer Center | Chief Tech/Sci/R&D Officer | 31/05/2003 |
| Asco Quality Symposium | Founder | - |
Training of Douglas Blayney
| University of California | Undergraduate Degree |
| Stanford University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARTELO BIOSCIENCES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| Stanford Cancer Institute | |
| Asco Quality Symposium |
- Stock Market
- Insiders
- Douglas Blayney
